Abstract
Objective: To investigate human epididymis protein 4 (HE4) levels in transitional cell carcinoma (TCC) of the urinary system and its relationship with clinicopathological features.
Methods: 102 patients with TCC, 60 with benign urinary diseases, and 60 healthy controls were included in this study. The HE4 levels were used to analyze different clinicopathologic characteristics and changes between pre‐ and postsurgical operation.
Results: The HE4 level was significantly increased in patients with TCC compared to patients with benign urinary diseases patients (P<0.01) and healthy controls (P<0.01), and the level of HE4 in patients with superficial TCC (Tis Ta T1) was significantly higher than that of the benign urogenital group (P<0.05)and healthy controls (P<0.05). There was a significant difference between HE4 levels in patients before and after operation (P<0.05). There was no difference between HE4 levels based on tumor recurrence, clinical TNM stage, lymph node metastasis, or pathological stage (P>0.05). The HE4 level was also different between patients with a single tumor versus patients with multiple tumors. The area under the curves of HE4 is 0.821. The sensitivity and specificity of HE4 at a cutoff value of 45.7 pM were 67.6 and 88.3%, respectively.
Conclusions: HE4 may be a screening tool for early diagnosis of TCC in the urinary system, and may become a prognostic marker for TCC in the urinary system. J. Clin. Lab. Anal. 23:357–361, 2009. © 2009 Wiley‐Liss, Inc.
Keywords: transitional cell carcinoma, human epididymis protein 4 (HE4), urologic diseases, biomarkers
REFERENCES
- 1. Shirai T. Etiology of bladder cancer. Semin Urol 1993;11:113–126. [PubMed] [Google Scholar]
- 2. Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis‐specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991;45:350–357. [DOI] [PubMed] [Google Scholar]
- 3. Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod 1998;3:86–95. [DOI] [PubMed] [Google Scholar]
- 4. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to wheyacidic protein. Biochem J 2002;368:233–242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002;21:2768–2773. [DOI] [PubMed] [Google Scholar]
- 6. Clauss A, Lilja H, Lundwall A. The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun 2005;333:383–389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999;229:101–108. [DOI] [PubMed] [Google Scholar]
- 8. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999;238:375–385. [DOI] [PubMed] [Google Scholar]
- 9. Hough CD, Sherman‐Baust CA, Pizer ES, et al. Large‐scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000;60:6281–6287. [PubMed] [Google Scholar]
- 10. Ono K, Tanaka T, Tsunoda T, et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000;60:5007–5011. [PubMed] [Google Scholar]
- 11. Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001;98:1176–1181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Shridhar V, Lee J, Pandita A, et al. Genetic analysis of early‐ vs. late‐stage ovarian tumors. Cancer Res 2001;61:5895–5904. [PubMed] [Google Scholar]
- 13. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003;14:4376–4386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004;10:3291–3300. [DOI] [PubMed] [Google Scholar]
- 15. Gilks CB, Vanderhyden BC, Zhu S, et al. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005;96:684–694. [DOI] [PubMed] [Google Scholar]
- 16. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162–2169. [DOI] [PubMed] [Google Scholar]
- 17. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267–277. [DOI] [PubMed] [Google Scholar]
- 18. Hellstrom I, Raycraft J, Hayden‐Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695–3700. [PubMed] [Google Scholar]
- 19. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 1986;83:6692–6696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Wiedow O, Schroder JM, Gregory H, et al. Elafin: An elastase‐specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem 1990;265:14791–14795. [PubMed] [Google Scholar]
- 21. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, et al. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 2003;100:5778–5782. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Devoogdt N, Revets H, Ghassabeh GH, et al. Secretory leukocyte protease inhibitor in cancer development. Ann NY Acad Sci 2004;1028:380–389. [DOI] [PubMed] [Google Scholar]
- 23. Tian X, Shigemasa K, Hirata E, et al. Expression of human kallikrein 7(hK7/SCCE) and its inhibitor antileukoprotease (ALP/SLPI) in uterine endocervical glands and in cervical adenocarcinomas. Oncol Rep 2004;12:1001–1006. [PubMed] [Google Scholar]
- 24. Robinson PA, Markham AF, Schalkwijk J, et al. Increase delafin expression in cystic, dysplastic and neoplastic oral tissues. J Oral Pathol Med 1996;25:135–139. [DOI] [PubMed] [Google Scholar]
- 25. Zhang M, Zou Z, Maass N, et al. Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. Cancer Res 1995;55:2537–2541. [PubMed] [Google Scholar]
- 26. Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008;110:196–201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402–408. [DOI] [PubMed] [Google Scholar]
- 28. Scholler N, Crawford M, Sato A, et al. Bead‐based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res 2006;12:2117–2124. [DOI] [PMC free article] [PubMed] [Google Scholar]